Drug development. Tufts Center

Tufts [University] Center for the Study of Drug Development, Tufts Center for the Study of Drug Development Pegs Cost of a New Prescription Medicine at 802 Million, press release, November 30, 2001. 

Tufts Center for the Study of Drug Development, Tufts CSDD Impact Report, 2005,1—4. 

Reichert, J.M. and Milne, C.-P., Public and private sector contributions to the discovery and development of "impact" drugs, A Tufts Center for the Study of Drug Development White Paper, May 2002. 

Out-of-pocket and capitalized costs per approved drug. (From Tufts University Center for the Study of C)rug Development.)... 

These data were obtained in April 2002 by Mom Janice Reichert at the Tufts University Center for Study of Drug Development in Boston, Massachusetts. For further trends and analyses in this regard, see the Tufts Center s Inc pact Report, Vol. 3, Nov/Dec 2001. 

Gosse, M.E., Manocchia, M., and Nelson, T.F., Overview of US Pharmaceutical Development, 1980-1994, Tufts University Center for the Study of Drug Development, May, 1996. Grabowski, H.G. and Vernon, J., The search for new vaccines the errors of the vaccines for children program, American Enterprise Institute, Washington, 1994. 

Sources. (1) PhRMA (Pharmaceutical Research and Manufacturers of America) Press Release dated November 14, 2006. http //www.who.int/mediacentre/factsheets/fs310/en/ index.html [accessed April 19, 2007], (2) CNN.com. Largest Passenger Jet Unveiled, January 18,2005. http //www.cnn.eom/2005/BUSINESS/01/18/airbus.380/ [accessed April 19, 2007], (3) Tufts Center for the Study of Drug Development, http //www.bizjournals.com/ sanfrancisco/stories/2006/12/04/newscolumn3.html [accessed September 26,2007]. 

Tufts Center for the Study of Drug Development. 2003. Total Cost to Develop a New Prescription Drug, Including Cost of Post-Approval Research, Is 897 mUlion. Press release, May 13, 2003. Available at www.csdd.tufts.edu. 

Tufts Center for the study of Drug Development http //csdd.tufts.edu/... 

Courses/ workshops/ and meetings are offered by the Pharmaceutical Education and Research Institute (PERI) (46)/ Drug Information Association (DIA) (47)/ Center for Drug Development Science (CDDS) at the University of California/ San FranciscO/ Washington/ D.C. Center (48)/ Tufts Center for the Study of Drug Development (CSDD-Tufts) (49)/ the National Institutes of Health (50)/ the FDA s Center for Drug Evaluation and Research (CDER)/ and other organizations. 

Tufts center for the study of drug development. In Backgrounder How New Drugs Move Through the Development and Approval Process, Tufts Centa for the study of Drug Development Boston, MA, 2001. 

Second, the percentage of US investigators participating in clinical trials has always been low, in the range of 5% of physicians, and this number seems to be declining. A recent study from the Tufts Center for the Study of Drug Development indicates that only 3% of US board certified physicians are principal investigators (Tufts University, 2005). 

Tufts Center for the Study of Drug Development. User Fees Credited with 51 % Drop in Average Approval Times Since 1993. In Tufts Center for the Study of Drug Development Impact Report ,, Iune 1999, Available at http // www.tufts.edu/med/csdd/impactl2.pdf. Accessed 2/22, 2001. 

FIGURE 2.1 The new drug approvals from 1963 to 2007 and corresponding R D expenditures. New drug approvals have not kept pace with rising R D spending. R D expenditure adjusted for inflation. (Courtesy of Tufts Center for the Study of Drug Development, Boston, MA. With permission.)... 

Tufts Center for the Study of Drug Development. 2005. Outlook 2005. Boston Tufts Center for the Study of Drug Development. http //csdd.tufts.edu/InfoServices/Out-lookPDFs/Outlook2005. pdf... 

---